Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study
Gemma Gatta(Fondazione IRCCS Istituto Nazionale dei Tumori), Anna Trama, Nadya Dimitrova(Istituto Superiore di Sanità), Roberta De Angelis(Istituto Superiore di Sanità), Laura Botta(Fondazione IRCCS Istituto Nazionale dei Tumori), Maja P Žakelj(Institute of Oncology Ljubljana), Otto Visser(Netherlands Comprehensive Cancer Organisation), Liesbet Van Eycken, Eva Ardanáz, Lesley Anderson(Queen's University Belfast), Sandra Mallone(Istituto Superiore di Sanità), Maarit K. Leinonen(University of Helsinki), Sabine Siesling(Netherlands Comprehensive Cancer Organisation), Charles Stiller(Unknown), Francesca Bella(Agenzia Regionale Sanitaria della Puglia), Innos Kaire(National Institute for Health Development), Riccardo Capocaccia(Departamento de Epidemiología), J. Van Der Zwan, R. Otter(Institut Scientifique de Santé Publique), Harry Comber(Universidad de Granada)
Research Portal (Queen's University Belfast)
July 4, 2017
Cited by 0
Related Papers
Current and future burden of breast cancer: Global statistics for 2020 and 2040
|The Breast|2022|3.3k
Meat, Fish, and Colorectal Cancer Risk: The European Prospective Investigation into Cancer and Nutrition
|JNCI Journal of the National Cancer Institute|2005|865
The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers
|European Journal of Cancer|2021|650
Body size and breast cancer risk: Findings from the European prospective investigation into cancer and nutrition (EPIC)
|International Journal of Cancer|2004|580
Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study
|The Lancet Oncology|2017|510